ZURICH (Reuters) - A COVID-19 vaccine like Pfizer and BioNTech's candidate is likely to need centralized vaccination locations, Swiss health experts said on Tuesday, as it must be stored at temperatures matching an Antarctic winter.
U.S.-based Pfizer and Germany's BioNTech said on Monday their mRNA vaccine candidate was more than 90% effective based on initial results, giving global markets an unexpected boost.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!